Journal article
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley, D Zukancic, A Algarni, H Al-Wassiti, TP Davis, CW Pouton, SJ Kent, NP Truong
Acta Biomaterialia | Published : 2021
Abstract
Vaccination represents the best line of defense against infectious diseases and is crucial in curtailing pandemic spread of emerging pathogens to which a population has limited immunity. In recent years, mRNA vaccines have been proposed as the new frontier in vaccination, owing to their facile and rapid development while providing a safer alternative to traditional vaccine technologies such as live or attenuated viruses. Recent breakthroughs in mRNA vaccination have been through formulation with lipid nanoparticles (LNPs), which provide both protection and enhanced delivery of mRNA vaccines in vivo. In this review, current paradigms and state-of-the-art in mRNA-LNP vaccine development are ex..
View full abstract